Australia markets open in 3 hours 14 minutes

Organon & Co. (OGN)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
29.69+0.11 (+0.37%)
As of 02:44PM EST. Market open.

Organon & Co.

30 Hudson Street
Floor 33
Jersey City, NJ 07302
United States
551 430 6000

IndustryDrug Manufacturers—General
Full-time employees10,000

Key executives

NameTitlePayExercisedYear born
Mr. Kevin AliCEO & Director3.08MN/A1960
Mr. Matthew M. WalshExec. VP & CFO1.57MN/A1967
Ms. Susanne Gabriele FiedlerExec. VP & Chief Commercial Officer1.51MN/A1968
Dr. Sandra Milligan J.D., M.D.Exec. VP and Head of R&D1.21MN/A1964
Ms. Rachel A. StahlerExec. VP & Chief Information OfficerN/AN/A1976
Ms. Jennifer HalchakVP of Investor RelationsN/AN/AN/A
Mr. Kirke WeaverGen. Counsel & Corp. Sec.N/AN/AN/A
Mr. Aaron FalcioneExec. VP & Chief HR OfficerN/AN/A1971
Mr. Joseph T. Morrissey Jr.Exec. VP and Head of Manufacturing & SupplyN/AN/A1965
Mr. Vittorio NisitaExec. VP & Head of Global Bus. ServicesN/AN/A1968
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.

Corporate governance

Organon & Co.’s ISS governance QualityScore as of 1 February 2023 is 6. The pillar scores are Audit: 7; Board: 1; Shareholder rights: 7; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.